Effects of Ketone Monoesters on Brain Function

Maastricht University Medical Centre (MUMC)

Status: Completed

Conditions: Appetite Control; Cerebral Blood Flow; Brain Vascular Function; Brain Insulin Sensitivity; Cognitive Performance

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Ketone Monoester

Study type: Interventional

Funder types: Other

Identifiers

NCT06395051

METC24-008

Details and patient eligibility

About

Disturbances in brain insulin-sensitivity are not only observed in obesity and type 2 diabetes (T2D), but also during brain aging and in dementia. Ketone monoester supplements may improve brain insulin-sensitivity, which can be quantified by measuring the gray-matter cerebral blood flow (CBF) response to intranasally administered insulin. We hypothesize that acute ketone monoester supplementation increases (regional) brain vascular function and insulin-sensitivity thereby improving cognitive performance and appetite control. The primary objective is to evaluate in older men the acute effect of ketone monoester supplementation on (regional) brain vascular function and insulin-sensitivity, as quantified by the non-invasive gold standard magnetic resonance imaging (MRI)-perfusion method Arterial Spin Labelling (ASL). The CBF response to intranasal insulin is a robust and sensitive physiological marker of brain insulin-sensitivity. Secondary objectives are to investigate effects on cognitive performance as assessed with a neuropsychological test battery, and appetite control as quantified by functional MRI (fMRI) with visual food cues.

Enrollment: 18 patients

Sex: Male

Ages: 60 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Men, aged between 60-75 years
• BMI between 25-30 kg/m2
• Fasting plasma glucose < 7.0 mmol/L
• Fasting serum TC < 8.0 mmol/L
• Fasting serum TAG < 4.5 mmol/L
• Systolic blood pressure < 160 mmHg and diastolic blood pressure < 100 mmHg
• Stable body weight (weight gain or loss < 3 kg in the past three months)
• Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study
• No difficult venipuncture as evidenced during the screening visit

Exclusion criteria

• Women
• Left-handedness
• Following a low-carbohydrate diet or consuming nutritional ketone supplements
• Current smoker, or smoking cessation < 12 months
• Diabetic patients
• Familial hypercholesterolemia
• Abuse of drugs
• More than 3 alcoholic consumptions per day
• Use of products or dietary supplements known to interfere with the main outcomes as judged by the principal investigators
• Use medication to treat blood pressure, lipid or glucose metabolism, or neurological or mental disorders.
• Use of an investigational product within another biomedical intervention trial within the previous 1-month
• Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis
• Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident
• Contra-indications for MRI imaging (e.g. pacemaker, surgical clips/material in body, metal splinter in eye, claustrophobia).

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

18 participants in 2 patient groups, including a placebo group

Experimental

Experimental group

Description:

Ketone monoesters

Treatment:

Dietary Supplement: Ketone Monoester

Placebo

Placebo Comparator group

Description:

Taste- and volume-matched placebo

Treatment:

Dietary Supplement: Placebo